|
Breakthrough Discovery in Nutritional Immunology
At the University of California at Berkeley, the
Chairman of the Nutritional Sciences Department
and
senior scientists from the molecular biology department were studying the
biological properties of Diindolylmethane (DIM), a naturally occurring
compound found in Brassica vegetables (broccoli, cauliflower, cabbage), when
they made a remarkable discovery:
DIM is a potent activator of the immune response
system with potent antiviral properties.
Since DIM is currently being used to
treat Recurring Respiratory Papillomatosis (RRP) caused by the Human
Papillomavirus (HPV) and an important human clinical study published in
November of 2009 demonstrated its effectiveness as a treatment for Cervical Dysplasia (a pre-cancerous condition also caused by HPV), this
discovery at UC Berkeley has been hailed as a scientific breakthrough that finally
explains DIM's potent activity against HPV.
ActivaMune is a patented formula exclusively
licensed from the University of California at Berkeley. The formula contains
a unique bioavailable formulation of Diindolylmethane (DIM) along with other
ingredients that work synergistically with it to modulate the immune system, support multiple organs throughout the body,
and fight infections such as HPV.
science
 Immune Modulation
ActivaMune's primary mode of action is that it
increases the sensitivity of cells in the body to the Interferon-Gamma
protein (IFN-G) in addition to increasing the body's Interferon-Gamma
production. Interferon-Gamma is a key signaling protein within the immune
system that boosts the ability of the body to defend itself against
bacterial and viral infections as well as cancer. Increasing
Interferon-Gamma sensitivity and production in the body enhances the immune
system's ability and agility to detect and eliminate viral infections--including
the HPV virus.
In addition to Interferon-Gamma, DIM also
stimulates the production of the Granulocyte
Colony Stimulating Factor (G-CSF) which is directly responsible for
White Blood Cell production in the body, Interlukin-6 (IL-6),
which is responsible for the body's direct anti-bacterial response,
and Interlukin-12 (IL-12) which stimulates the growth and function of
T-Cells which help to fight off pathogens.
Discoverers of DIM
The discoverers
of Diindolylmethane as a potent immune system activator are: Dr. Leonard
Bjeldanes, Professor and Former Chairman of the Department of Nutritional
Sciences and Toxicology at UC Berkeley and Dr. Gary Firestone, Professor and Director of the National Institutes of Health Cancer Research Program at UC
Berkeley. Dr. Bjeldanes and Dr. Firestone are regarded as leading scientific
authorities on Diindolylmethane as together they have published more papers
on DIM than any other research team worldwide.
As immune modulation does not discriminate in the type of infection that it
combats, DIM is currently under investigation as a therapeutic
candidate for all viral and bacterial infections known to man, including
HIV, Hepatitis and antibiotic resistant bacteria.
ActivaMune's
Formula
ActivaMune is the first all natural formula in the market
that combines multiple ingredients proven to synergize in their immune
modulatory and anti-viral activity: Diindolylmethane, Sulforaphane,
Selenium, Lycopene, Lutein, Zeaxanthin, Vitamin E and Vitamin C.
The Scientific Advisory Board members of our
company are internationally renowned scientists in the fields of nutrition,
oncology and immunology:
Dr. Leonard Bjeldanes, Ph.D. Professor and Former
Chairman, Nutritional Sciences Department, UC Berkeley. Dr. Bjeldanes is the
most cited scientist worldwide in the field of Diindolylmethane research.
Dr. Gary
Firestone, Ph.D. Director, National Institutes of Health Cancer Research Program, UC Berkeley.
Dr. Firestone and Dr. Bjeldanes at UC Berkeley have together published more
scientific papers on DIM than any other scientific team worldwide.
Dr. Christopher Benz, M.D. Professor of Medicine in Oncology, UCSF, founder of the first laboratory at UCSF dedicated to breast cancer research, Program Director, Cancer and Developmental
Therapeutics Program, Buck Institute for Age Research.
Dr. Warner Greene, M.D., Ph.D. Professor of Medicine in Immunology, UCSF, Director,
UCSF Gladstone Institute of Virology and Immunology, Board Member,
United States Institute of Medicine, National Academy of Sciences.
Dr. Giuseppe Del Priore, M.D., M.P.H.
Professor of Medicine and Director of Gynecologic Oncology at the Indiana
University School of Medicine. Dr. Del Priore led the successful human clinical
trials of DIM for the treatment of Cervical Dysplasia caused by the HPV virus.
Human Clinical Study
Confirming Effectiveness for Cervical Dysplasia Caused by HPV
In November of 2009 biomedical investigators at the Indiana University
School of Medicine in collaboration with colleagues at the New York Downtown
Hospital published the results of an important human clinical study in which
they showed that DIM is indeed highly efficacious for HPV infections and
Cervical Dysplasia. This study has helped to further confirm the potent
antiviral properties of Diindolylmethane which was discovered at UC Berkeley.
For a review of this study and its details please visit the
News and
References
sections of our website. An abstract of this important study is hereby presented
below.
If until now your doctor has told you that there are no
treatment options for HPV except surgery, ask your doctor to take a close look at this
important human clinical study.
Oral diindolylmethane (DIM): Pilot evaluation of a nonsurgical
treatment for cervical dysplasia. Gynecological Oncology. 2009 Nov 24. Del
Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA.
Indiana University School of Medicine, Dept of Ob-Gyn, Div Gyn Oncology,
Indianapolis, IN, USA; Research Department, New York Downtown Hospital-member
NY-Presbyterian Healthcare, New York, NY, USA.
OBJECTIVE: Standard surgical treatment for CIN may impair fertility generating a
need for alternative treatment options. We tested the efficacy and toxicity of
oral DIM in the treatment of CIN 2 or 3 lesions. METHODS: Patients with
biopsy-proven cervical intraepithelial neoplasia (CIN) 2 or 3 scheduled for loop
electrosurgical excision procedure (LEEP) were randomized 2:1 to receive
diindolylmethane (DIM) orally at approximately 2 mg/kg/day for 12 weeks or
placebo. Subjects were evaluated every 3-4 months for 1 year. Analysis of data
up to 1 year was assessed including Pap smear, HPV, colposcopy, biopsy and
physical examination were performed at follow-up. Central pathology review
confirmed all histology diagnoses. RESULTS: To date, 64 subjects (mean age 28
years, range 18-61) have been enrolled (45 in the DIM arm, 19 in the placebo
arm), with 60 available for analysis. Average follow-up was 6 months. At
enrollment, 58% were diagnosed with CIN 2 and 42% with CIN 3, 57% of subjects
were Caucasian, 15% African American, 12% Hispanic and 17% Asian. During
treatment 2 subjects (3%) complained of nausea (grade 2) at the 3- to 4-month
visit. No systemic toxicities were observed (normal CBC, LFTs, comprehensive
metabolic). Forty-six subjects had biopsies at first follow-up (77%). Twenty-one
subjects (47%) in the DIM group had improved CIN with a decrease by 1-2 grades
or a normal result. Median time to improvement was 5 months. Improved Pap smear
was
seen in 49% (22/45) with either a less severe abnormality or normal result.
Colposcopy improved in twenty-five subjects in the DIM group (56%). Of these 25
subjects, 21 (84%) had improved colposcopic impression, 13 (52%) had a decrease
in involved quadrants and 18 (72%) had a decrease in lesion number. Complete
colposcopic response was observed in 4 subjects (9%). Stratifying by level of
dysplasia, age, race, HPV status, tobacco use, contraceptive used did not alter
the results. At median follow-up of 6 months, 85% of subjects have not required
LEEP based on routine clinical triage of improving global assessment. CONCLUSION: Oral DIM at 2 mg/kg/day is well tolerated with no
significant toxicity.
We observed a high rate of clinically significant
improvement in confirmed CIN 2 or 3 lesions among both treatment groups in this
randomized clinical trial.
Customer Testimonials
"In just four months I went from severe cervical
dysplasia to no sign of dysplasia. Thank you Berkeley BioSciences for giving
me my life back."
Janet R., Berkeley, California
"In two months I went from severe cervical dysplasia to
mild dysplasia. I'm thrilled to see that I'm getting better. Thank you for
all of your assistance!"
Dianne S., Los Angeles, California
"Six months after taking ActivaMune I'm proud to say
that all my genital warts have disappeared! This is very exciting. Bravo
Berkeley. Bravo!"
Brian A., Las Vegas, Nevada
"Four months into the program and I'm completely wart
free. Thank you for an outstanding product."
John M., New York, New York
"I've been taking ActivaMune for five months now and I
have not had to go in for surgery! My RRP has subsided! Thank you for all of
your assistance."
Rosemary R., Chicago, Illinois
ActivaMune Formulation
ActivaMune's patented formulation from UC Berkeley
contains DIM in addition to many other ingredients engineered to
significantly enhance the antiviral properties of DIM, and as such, the
formula is far more effective than taking DIM alone.
Dosage Recommendation for
HPV Patients
Physicians who have successfully administered our product to
their patients suggest that HPV patients take 4 capsules a day or
ActivaMune for a period of at least six months in order to see
significant improvements in their conditions. You will also note from the
study abstract above that as a naturally occurring compound DIM is effective
over a long period of time.
Partners Taking the Product
Because HPV is a sexually transmitted disease and condoms do
not provide effective protection against this disease, if a patient plans on
continuing to have intimacy with their partner while undergoing treatment,
it is highly recommended that their partner also take ActivaMune at a dosage
of 4 capsules a day during the period that the patient is undergoing
treatment. If a patient's partner does not take the immune enhancing product
during the patient's treatment period and intimacy occurs, there is a risk
that the partner who may have previously been infected by the patient,
re-infects the patient with HPV rendering the product less effective.
Because of this, we strongly suggest that partners also take the product at
4 capsules a day during the patient's treatment period so that a bilateral
protection is enabled. Of course, if the patient plans to abstain from all
sexual relationships with their partner during the treatment period, then
there would be no reason for the partner to take the product if they do not
display any HPV symptoms.
Visit Our Main Website to
Learn More
This is our HPV welcome page.
Please click here to visit ActivaMune's home page and
begin your tour of our website. Throughout our website, you
will come across a lot of references to ActivaMune's anti-cancer properties.
This is because immune modulation also has potent anti-cancer properties and
the same molecular mechanism that displays viral antigens to the immune
system leading to their destruction is also used to display cancer antigens,
helping the immune system to identify and destroy cancerous cells.
If you have any questions about ActivaMune, please feel free to call our customer service number at
1-877-777-0719 and we will be happy to assist you. Our product is backed by
a 100% satisfaction guarantee.
Once again, welcome and we hope that you find your visit to
be informative.
| 
